Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
Steven M. Paul, Samantha E. Yohn, Michael Popiolek, et al.
American Journal of Psychiatry (2022) Vol. 179, Iss. 9, pp. 611-627
Closed Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Inder Kaul, Sharon Sawchak, Christoph U. Correll, et al.
The Lancet (2023) Vol. 403, Iss. 10422, pp. 160-170
Closed Access | Times Cited: 97
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 60
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia
Inder Kaul, Sharon Sawchak, David P. Walling, et al.
JAMA Psychiatry (2024) Vol. 81, Iss. 8, pp. 749-749
Open Access | Times Cited: 54
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 51
Psychotropic Drug–Related Weight Gain and Its Treatment
Roger S. McIntyre, Angela T.H. Kwan, Joshua D. Rosenblat, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 1, pp. 26-38
Closed Access | Times Cited: 43
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
S. Paul, Samantha E. Yohn, Stephen K. Brannan, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 627-637
Open Access | Times Cited: 21
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 17
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
William P. Horan, Steven D. Targum, Amy Claxton, et al.
Schizophrenia Research (2024) Vol. 274, pp. 57-65
Open Access | Times Cited: 17
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 16
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
Colin Sauder, Luke Allen, Elizabeth Baker, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 66
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 62
Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
Christoph U. Correll, Angel S. Angelov, Andrew Miller, et al.
Schizophrenia (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 42
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
Alan Breier, Stephen K. Brannan, Steven M. Paul, et al.
Psychopharmacology (2023) Vol. 240, Iss. 5, pp. 1191-1198
Open Access | Times Cited: 38
Finding new and better treatments for psychiatric disorders
Steven M. Paul, William Z. Potter
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 3-9
Open Access | Times Cited: 34
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis
Nicholas Fabiano, Stanley Wong, Carl Zhou, et al.
European Neuropsychopharmacology (2024) Vol. 92, pp. 62-73
Open Access | Times Cited: 10
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
Alexia Leber, Ranuk Ramachandra, Felicia Ceban, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 467-476
Open Access | Times Cited: 8
Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application
Stefan Leucht, Josef Priller, John M. Davis
American Journal of Psychiatry (2024) Vol. 181, Iss. 10, pp. 865-878
Closed Access | Times Cited: 8
Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes
Taro Kishi, Leslie Citrome, Kenji Sakuma, et al.
Pharmacopsychiatry (2025)
Closed Access | Times Cited: 1
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
W. P. Horan, Amir H Kalali, Stephen K. Brannan, et al.
Schizophrenia Bulletin (2025)
Open Access | Times Cited: 1
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis
Liangkun Guo, Yi Su, Yuyanan Zhang, et al.
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Vagus nerve stimulation as a promising neuroprotection for ischemic stroke via α7nAchR-dependent inactivation of microglial NLRP3 inflammasome
Xiaomei Xia, Yu Duan, Yueping Wang, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 7, pp. 1349-1365
Closed Access | Times Cited: 7
Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment
Ali Azargoonjahromi
Clinical Drug Investigation (2024) Vol. 44, Iss. 7, pp. 471-493
Closed Access | Times Cited: 7
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Inder Kaul, Sharon Sawchak, Amy Claxton, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline–Trospium Combination: A Systematic Review
Octavian Vasiliu, Beatrice Budeanu, Mihai-Ștefan Cătănescu
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 610-610
Open Access | Times Cited: 6
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases
Andrew B. Tobin
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 10, pp. 743-758
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top